^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SMART 101
i
Other names: SMART 101, SMART101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Smart Immune
Drug class:
Cell therapy
Related drugs:
7ms
SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: SI101-02 First-in-Human Phase I/II (ASH 2023)
Conclusion SMART101 is the first-generation of allogeneic TLP cell therapy obtained from Smart Immune's proprietary GMP manufacturing platform. The duration and the depth of T cell immunodeficiency post haplo PTCy HSCT is expected to be significantly reduced by the infusion of SMART101 thereby decreasing the non-relapse mortality and morbidity rates and thus improving the overall clinical outcome of this therapy.
P1/2 data • Post-transplantation
|
CD34 (CD34 molecule) • CD7 (CD7 Molecule)
|
cyclophosphamide • SIRPant-M (SI-101) • SMART 101
8ms
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide (clinicaltrials.gov)
P1/2, N=40, Recruiting, Smart Immune SAS | Trial completion date: Oct 2026 --> Jul 2026 | Trial primary completion date: Jan 2025 --> Jul 2025
Trial completion date • Trial primary completion date • Post-transplantation
|
CD4 (CD4 Molecule)
|
cyclophosphamide • SMART 101
10ms
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide (clinicaltrials.gov)
P1/2, N=34, Recruiting, Smart Immune SAS | Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Jun 2023
Enrollment open • Trial initiation date
|
CD4 (CD4 Molecule)
|
cyclophosphamide • SMART 101
1year
SI101-01 PHASE I/II STUDY EVALUATING SAFETY AND EFFICACY OF ALLOGENEIC SMART101 T-LYMPHOID PROGENITOR INJECTION TO ACCELERATE IMMUNE RECONSTITUTION AFTER T-CELL DEPLETED ALLOGENEIC HSCT (EHA 2023)
SMART101 is the first-generation of allogeneic T lymphoid progenitor cells obtained through Smart Immune's ProTcell platform, the first scalable progenitor T-cell manufacturing system in clinics. The early data indicate that SMART101 is well tolerated with a good safety profile. Thymic function, Post-transplant, CD4+ T cells, Allogeneic hematopoietic stem cell transplant
Clinical • P1/2 data
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD34 (CD34 molecule) • CD7 (CD7 Molecule) • MLANA (Melan-A) • KLRB1 (Killer Cell Lectin Like Receptor B1)
|
SIRPant-M (SI-101) • SMART 101
1year
SMART101 DONOR T-LYMPHOID PROGENITORS TO ACCELERATE IMMUNE RECONSTITUTION POST-HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE: SI101-02 PHASE I/II (EHA 2023)
SMART101 is the first-generation of allogeneic T lymphoid progenitor cell therapy obtained from Smart Immune's proprietary ProTcell platform, the first scalable progenitor T-cell manufacturing system in clinics. Notch, Thymus, Post-transplant, Allogeneic hematopoietic stem cell transplant
P1/2 data • Post-transplantation
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD34 (CD34 molecule) • CD7 (CD7 Molecule) • MLANA (Melan-A) • KLRB1 (Killer Cell Lectin Like Receptor B1) • SELP (Selectin P)
|
cyclophosphamide • SIRPant-M (SI-101) • SMART 101
1year
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide (clinicaltrials.gov)
P1/2, N=34, Not yet recruiting, Smart Immune SAS
New P1/2 trial • Post-transplantation
|
CD4 (CD4 Molecule)
|
cyclophosphamide • SMART 101
1year
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT (clinicaltrials.gov)
P1/2, N=36, Recruiting, Smart Immune SAS | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Mar 2025 --> Aug 2025
Trial completion date • Trial primary completion date
|
TP53 (Tumor protein P53) • CD4 (CD4 Molecule)
|
TP53 mutation
|
SMART 101
over2years
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Acute Leukemia After T Cell Depleted Allo-HSCT (clinicaltrials.gov)
P1/2, N=36, Recruiting, Smart Immune SAS | Not yet recruiting --> Recruiting | Trial completion date: Sep 2026 --> Dec 2026 | Initiation date: Sep 2021 --> Dec 2021 | Trial primary completion date: Dec 2024 --> Mar 2025
Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
SMART 101
almost3years
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Acute Leukemia After T Cell Depleted Allo-HSCT (clinicaltrials.gov)
P1/2, N=36, Not yet recruiting, Smart Immune SAS
Clinical • New P1/2 trial
|
CD4 (CD4 Molecule)
|
SMART 101
Share via
